Magazine Article | January 4, 2022

Companies To Watch: Qlaris Bio

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Striking at an unaddressed target in the intraocular pressure of glaucoma


Qlaris Bio (que-lar-is) is a private company developing ophthalmology medicines. Although the company has several compounds in discovery and early development, it has publicly discussed only its lead candidate, coded QLS-101, which is in early-stage trials for three ocular conditions. QLS-101 is in a Phase 2 trial for primary open-angle glaucoma and ocular hypertension; another Phase 2, for normal tension glaucoma; and a Phase 2, for adults with Sturge-Weber syndrome. The drug uses a novel mechanism of action to target a heretofore unaddressed factor in intraocular pressure (IOP), the central actor in glaucoma. The factor is episcleral venous pressure (EVP), the only one of the four factors in IOP that no current drug on the market addresses.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader